Loading...

CELU CELULARITY INC Other Situations 8-K Filing

CLLR

CL

CELULARITY INC

(CELU)

2023 8-K

FDA Warning Letter

Funding Agreement

Nasdaq Compliance Notice

Asset Sale Agreement

Debt-Equity Swaps

Stock Offerings

Warrants Repricing

Equity Offerings

Financial Statements

Voluntary Delisting

Delisting due to Non-Compli...

Equity Agreement

Collaboration Agreement

Loan Extensions

Warrant Amendment

Agreement Termination

Securities Agreement

Annual Meeting Results

Securities Agreement

Nasdaq Compliance Issue

Annual Meeting Notice

Sales Guidance Update

Revenue Expectations

Nasdaq Compliance Issue

Asset Acquisition

Management Change

Director Appointment

Changes in Management and C...

Financial Results

Equity Purchase Agreement

Reverse Stock Split

Salary Reduction for Execut...

Regulation FD Disclosure

Private Placement and Senio...

Earnings Report

Resignation of Director

Agreement Extension, Resign...

Management Changes

Resignation of Director

Securities Purchase Agreement

Entry into a Material Defin...

Annual Meeting Approval

Publication of Corporate Pr...

Private Placement

Preliminary Trial Results

Securities Purchase Agreement

Private Placement, Loan Agr...

CEO Salary Suspension and B...

External Links:

Celularity Inc. announced preliminary results from its Phase 1 trial of CYNK-001 for the treatment of relapsed refractory acute myeloid leukemia (AML) and measurable residual disease-positive AML.

AI Assistant

CELULARITY INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.